Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

How to Avoid Insurance Denials for Prescribing a Biologic Without MTX in Concert

From the College  |  February 15, 2018

The Insurance Subcommittee (ISC) of the ACR’s Committee on Rheumatologic Care (CORC) has recently received a number of reports from members regarding denials for biologics for patients not on methotrexate. To help avoid an often-lengthy appeals process, the ACR/ARHP recommends that members document a patient’s history of methotrexate intolerance or contraindication at every visit.

What to Document
At minimum, documentation of each patient encounter should include:

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
  • The reason for the visit;
  • The relevant history;
  • Physical exam findings;
  • Prior diagnostic test results;
  • Assessment, clinical impression or diagnosis; and
  • Plan of care.

The patient’s progress and response to and changes in treatment(s) and revisions should also be documented.

Some of these areas may be adjusted to account for the varying circumstances encountered by the provider at each visit, but it is important to ensure the necessary documentation is in the patient’s medical record to support the level of care.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Documenting the Biologic/Methotrexate Combo
For biologics normally prescribed in combination with methotrexate, consistently documenting the reason for the exception, ideally at each encounter, is key to ensuring timely payment by the insurance company. Documenting this reason is important even for patients on long-term therapy. The payer will review the chart notes submitted with each claim; however, there is no guarantee they will have access to previous claims or health records. Therefore, documenting the intolerance or contraindication at every visit ensures the payer has the necessary information to approve the claim without delay.

Need Help?
If you have a patient with an insurance policy that prohibits biologic monotherapy, regardless of the patient’s ability to tolerate methotrexate, let the ISC know. Also, ACR coders are available to assist with any coding guidelines or chart reviews for required clinical documentation for individual claims. Send an email to [email protected] for further details.

Share: 

Filed under:From the CollegePractice Support Tagged with:BiologicsCommittee on Rheumatologic Care (CORC)Documentationinsurance denialsInsurance SubcommitteeMethotrexate

Related Articles

    New Wins, Ongoing Challenges for ACR Insurance Subcommittee

    July 3, 2019

    Corrections to reimbursement system errors with Aetna and a Medicare contractor demonstrate the latest wins for all providers by the ACR’s Insurance Subcommittee. But the committee remains hard at work advocating for rheumatologists on several fronts.

    Protect Your Practice: Action Update From the ACR’s Insurance Subcommittee

    November 5, 2018

    Both private and academic rheumatology practices face payer challenges that put the health of their patients and their practices at risk. To make sure the rheumatologist perspective is heard by payers, “the ACR’s Insurance Subcommittee (ISC) serves as the interface between payers and our members and ACR colleagues,” explains Sean Fahey, MD, a rheumatologist in…

    ACR Insurance Subcommittee Chair Encourages Member Engagement

    January 20, 2022

    Rheumatology practices have a voice in payer advocacy through the Insurance Subcommittee of the ACR’s Committee on Rheumatologic Care.

    Practice Page: The ACR’s Insurance Subcommittee Facilitates Better Communication With Health Insurers for Rheumatology Practices

    June 1, 2013

    Committee is working to develop policy and programs to help ACR members deal with the administrative requirements of health insurance plans

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences